CAJ | 학술논문

目的：对三氧化二砷联合化疗药物治疗急性早幼粒细胞白血病的临床治疗效果进行评价并对其安全性进行分析。方法选取自2010年1月至2011年6月接受治疗的首诊为急性早幼粒细胞白血病患者共46例，对所有的患者采用三氧化二砷诱导后，应用化疗药物米托蒽醌以及阿糖胞苷进行治疗。进行为期3年的随访收集资料并分析治疗效果，即对完全缓解率、三年内复发率、三年内生存率和死亡情况以及并发症情况进行相关处理后分析。结果在46例研究对象接受三氧化二砷联合化疗治疗后，有42例完全缓解，完全缓解率为91.3%。所有患者进行化疗治疗后，死亡4例，总并发症率为71.7%（33/46）；第一年复发率为7.1%（3/42），第二年复发率为23.8%（10/42），第三年复发率为35.7%（15/42）。第一年病死率为2.4%（1/42），第二年病死率为9.5%（4/42），第三年的病死率为21.4%（9/42）。结论三氧化二砷联合化疗药物对急性早幼粒细胞白血病进行治疗后，能够显著提高患者的生存率以及生活质量，毒性反应小，完全缓解率高，用药安全，值得在临床推广应用。
목적：대삼양화이신연합화료약물치료급성조유립세포백혈병적림상치료효과진행평개병대기안전성진행분석。방법선취자2010년1월지2011년6월접수치료적수진위급성조유립세포백혈병환자공46례，대소유적환자채용삼양화이신유도후，응용화료약물미탁은곤이급아당포감진행치료。진행위기3년적수방수집자료병분석치료효과，즉대완전완해솔、삼년내복발솔、삼년내생존솔화사망정황이급병발증정황진행상관처리후분석。결과재46례연구대상접수삼양화이신연합화료치료후，유42례완전완해，완전완해솔위91.3%。소유환자진행화료치료후，사망4례，총병발증솔위71.7%（33/46）；제일년복발솔위7.1%（3/42），제이년복발솔위23.8%（10/42），제삼년복발솔위35.7%（15/42）。제일년병사솔위2.4%（1/42），제이년병사솔위9.5%（4/42），제삼년적병사솔위21.4%（9/42）。결론삼양화이신연합화료약물대급성조유립세포백혈병진행치료후，능구현저제고환자적생존솔이급생활질량，독성반응소，완전완해솔고，용약안전，치득재림상추엄응용。
Objective The aim of our retrospective study was to analyze the clinical treatment effect of rational evaluation and its safety based on 46 cases of acute promyelocytic leukemia with arsenic trioxide combined with chemotherapy drugs application. Methods Clinical data of patients to our hospital for treatment of first diagnosis of promyelocytic leukemia cells from January 2010 to June 2011 was retrospectively analyzed. After arsenic trioxide induced,chemotherapy drug mitoxantrone quinone and cytarabine were used for treatment. Data collection and treatment effect for a period of 3 years of follow - up were analyzed. The complete remission rate,recurrence rate within three years,three years survival rate,death,complications were related to the processing analysis. Results A total of patients were retrospective analyzed. After arsenic trioxide combined with chemotherapy in the treatment in 46 cases,there were 42 cases of complete remission and complete remission rate was 91. 3% . Af-ter chemotherapy in the treatment of all patients,4 cases died,and the total complication rate was 71. 7%(33 / 46). First year recurrence rate of all patients was 7. 1%(3 / 42). The second year recurrence rate was 23. 8%(10 / 42). The third year recurrence rate was 35. 7%(15 / 42). The mortality rate of all patients during the first year was 2. 4%(1 / 42). Mortality rate during second year was 9. 5%(4 / 42). Mortality rate during third year was 21. 4%(9 / 42). Conclusion Arsenic trioxide combined with chemotherapy for treatment of APL can significantly increase the sur-vival rate and quality of life. The poisonous side reaction is small. The complete remission rate is high. The drug is safe. Large range populariza-tion and application is worth in the clinical practice.